Upon receiving accelerated approval, drug manufacturers are required to conduct post-approval studies to confirm the clinical benefits of the drug. These studies aim to verify that the surrogate endpoints translate into actual clinical improvements, such as longer survival rates or better quality of life for patients. If the post-approval studies fail to confirm the anticipated benefits, the FDA has the authority to withdraw the drug from the market.
